Cell and Gene Therapy Catapult, UCLB and Imperial Innovations announce positive interim review in ongoing AML WT1 T cell clinical trial
Hundreds of thousands of people worldwide, who have a disease that can lead to blindness, could have their sight restored after The University of Manchester entered into a technology license with Seattle-based company Acucela Inc.